Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Fiche publication
Date publication
mars 2017
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland, Dr ZANETTA Sylvie, Pr REIMUND Jean-Marie
Tous les auteurs :
Dupont B, Mariotte D, Dugué AE, Clarisse B, Grellard JM, Babin E, Chauffert B, Dakpé S, Moldovan C, Bouhier-Leporrier K, Reimund JM, Di Fiore F, Zanetta S, Mailliez A, Do P, Peytier A, Galais MP, Florescu C, Schott R, Le Mauff B, Gervais R
Lien Pubmed
Résumé
Cetuximab is an anti-epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti-cetuximab immunoglobulin E (IgE) detection in order to identify patients at risk of HSR to cetuximab.
Mots clés
anaphylaxis, anti-immunoglobulin E antibodies, cetuximab, hypersensitivity
Référence
Br J Clin Pharmacol. 2017 Mar;83(3):623-631